AbCellera Biologics Inc. (ABCL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABCL POWR Grades
- Value is the dimension where ABCL ranks best; there it ranks ahead of 92.95% of US stocks.
- ABCL's strongest trending metric is Quality; it's been moving down over the last 177 days.
- ABCL's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).
ABCL Stock Summary
- ABCL's went public 2.13 years ago, making it older than just 9.39% of listed US stocks we're tracking.
- Of note is the ratio of ABCELLERA BIOLOGICS INC's sales and general administrative expense to its total operating expenses; merely 10.58% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of 162.58%, ABCELLERA BIOLOGICS INC's debt growth rate surpasses 91.57% of about US stocks.
- Stocks that are quantitatively similar to ABCL, based on their financial statements, market capitalization, and price volatility, are ASTR, VRCA, AMWL, CORT, and VRAR.
- To check out ABCELLERA BIOLOGICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001703057.
ABCL Valuation Summary
- ABCL's price/sales ratio is 4.9; this is 139.02% higher than that of the median Healthcare stock.
- Over the past 26 months, ABCL's price/sales ratio has gone down 1344.1.
Below are key valuation metrics over time for ABCL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABCL | 2023-01-20 | 4.9 | 2.4 | 11.9 | 7.3 |
| ABCL | 2023-01-19 | 4.8 | 2.3 | 11.7 | 7.2 |
| ABCL | 2023-01-18 | 4.9 | 2.4 | 12.0 | 7.3 |
| ABCL | 2023-01-17 | 5.0 | 2.4 | 12.1 | 7.5 |
| ABCL | 2023-01-13 | 4.9 | 2.4 | 12.0 | 7.3 |
| ABCL | 2023-01-12 | 4.8 | 2.3 | 11.7 | 7.2 |
ABCL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ABCL has a Quality Grade of C, ranking ahead of 74.92% of graded US stocks.
- ABCL's asset turnover comes in at 0.453 -- ranking 98th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ABCL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.453 | 1 | 1.811 |
ABCL Price Target
For more insight on analysts targets of ABCL, see our ABCL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $45.40 | Average Broker Recommendation | 1.3 (Strong Buy) |
ABCL Stock Price Chart Interactive Chart >
ABCL Price/Volume Stats
| Current price | $10.76 | 52-week high | $14.97 |
| Prev. close | $10.52 | 52-week low | $5.42 |
| Day low | $10.39 | Volume | 1,247,344 |
| Day high | $10.85 | Avg. volume | 1,591,451 |
| 50-day MA | $11.15 | Dividend yield | N/A |
| 200-day MA | $10.34 | Market Cap | 3.08B |
AbCellera Biologics Inc. (ABCL) Company Bio
AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics. It was founded in 2012 and headquartered in Vancouver, British Columbia.
Latest ABCL News From Around the Web
Below are the latest news stories about ABCELLERA BIOLOGICS INC that investors may wish to consider to help them evaluate ABCL as an investment opportunity.
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023VANCOUVER, British Columbia, January 24, 2023--AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 |
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately. |
AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS RatingA Relative Strength Rating upgrade for AbCellera Biologics shows improving technical performance. |
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture PatentVANCOUVER, British Columbia, January 20, 2023--AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent |
Does AbCellera Biologics (NASDAQ:ABCL) Deserve A Spot On Your Watchlist?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks... |
ABCL Price Returns
| 1-mo | 12.43% |
| 3-mo | -8.11% |
| 6-mo | 7.17% |
| 1-year | 38.48% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 6.22% |
| 2022 | -29.16% |
| 2021 | -64.46% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...